Ionis Pharmaceuticals, Inc. is looking to initiate a Phase III trial for ION582 as quickly as possible based on positive data announced on 22 July from the Phase I/II open-label HALOS study in people with the rare neurological condition Angelman syndrome (AS).
“Our top priority is to gain alignment with the FDA rapidly and to move ION582 into Phase III development as early as possible next year,” CEO Brett Monia said during a same-day call outlining the data